Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Mapp Gets U.S. Funds To Develop Ebola Drug

by Rick Mullin
September 8, 2014 | A version of this story appeared in Volume 92, Issue 36

The Department of Health & Human Services has signed a $24.9 million, 18-month contract with Mapp Biopharmaceutical to support the development and manufacturing of ZMapp, an experimental drug that has been given to some Ebola patients. Under the contract, Mapp will manufacture a small amount of the drug to demonstrate safety and efficacy in humans. Mapp will also work with HHS’s Biomedical Advanced Research & Development Authority to improve the manufacturing process for the drug, which is a combination of three monoclonal antibodies grown in tobacco plants. It is currently in extremely short supply.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.